S
Sigrun Hallmeyer
Researcher at Advocate Lutheran General Hospital
Publications - 41
Citations - 3532
Sigrun Hallmeyer is an academic researcher from Advocate Lutheran General Hospital. The author has contributed to research in topics: Coxsackievirus A21 & Melanoma. The author has an hindex of 16, co-authored 37 publications receiving 2210 citations. Previous affiliations of Sigrun Hallmeyer include University of Washington.
Papers
More filters
Journal ArticleDOI
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer,Christina Lacchetti,Bryan J. Schneider,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marc S. Ernstoff,Jennifer M. Gardner,Pamela K. Ginex,Sigrun Hallmeyer,Jennifer Holter Chakrabarty,Natasha B. Leighl,Jennifer S. Mammen,David F. McDermott,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura Diane Porter,Igor Puzanov,Cristina A. Reichner,Bianca Santomasso,Carole Seigel,Alexander Spira,Maria E. Suarez-Almazor,Yinghong Wang,Jeffrey S. Weber,Jeffrey S. Weber,Jedd D. Wolchok,John A. Thompson +29 more
TL;DR: Recommendations for specific organ system-based toxicity diagnosis and management are presented and, in general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, with the exception of endocrinopathies that have been controlled by hormone replacement.
Journal ArticleDOI
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Andrey Meshcheryakov,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf,Rutger H. T. Koornstra,Leonel Hernandez-Aya,Anna Maria Di Giacomo,Alfonsus J M van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Paul Lorigan,Alexander C.J. van Akkooi,Clemens Krepler,Nageatte Ibrahim,Sandrine Marreaud,Michal Kicinski,Stefan Suciu,Caroline Robert,Alex Menzies,Thierry Lesimple,Michele Maio,Gerald P. Linette,Michael C. Brown,Peter Hersey,Inge Marie Svane,Laurent Mortier,Jacob Schachter,Catherine Barrow,Ragini R. Kudchadkar,Xinni Song,Caroline Dutriaux,Pietro Quaglino,Friedegund Meier,Paola Queirolo,Daniil Stroyakovskiy,Lars Bastholt,Bernard Guillot,Claus Garbe,Pablo Luis Ortiz Romero,Florent Grange,Peter Mohr,Alain Algazi,Oliver Bechter,Micaela Hernberg,Jean-Philippe Arnault,Philippe Saiag,Carmen Loquai,Frank Meiss,Jan-Christoph Simon,Gil Bar-Sela,Vanna Chiarion Sileni,Bernard Fitzharris,Mike McCrystal,Phillip Parente,Jean-Francois Baurain,Patrick Combemale,Céleste Lebbé,Axel Hauschild,Naoya Yamazaki,Reinhard Dummer,Mohammed M. Milhem,Marcin Dzienis,John Walker,Lionel Geoffrois,Marie-Thérèse Leccia,Lutz Kretschmer,Daniel Hendler,Michal Lotem,Andrzej Mackiewicz,Lidija Sekulovic,Elaine Dunwoodie,Christoph Hoeller,Laurent Machet,Jessica C. Hassel,Geke A. P. Hospers,Maria-Jose Passos,Max Levin,Martin Fehr,Philippa Corrie,Ashita Waterston,Sigrun Hallmeyer,Henrik Schmidt,Vincent Descamps,Jean-Philippe Lacour,Carola Berking,Felix Kiecker,Pier Francesco Ferrucci,Kenji Yokota,Maureen J.B. Aarts,Michael B. Jameson,Anna Katharina Winge-Main,Paula Ferreira,Kevin B. Kim,Catriona M. McNeil,Reiner Hofmann-Wellenhof,Joseph Kerger,François Aubin,Jochen Utikal,Virginia Ferraresi,Takashi Inozume,Yoshio Kiyohara,Gerard Groenewegen,Helena Kapiteijn,Suzana Matkovic,Wolf-Henning Boehncke,Richard Casasola,Timothy Crook,Ernest Marshall,Tanja Skytta,Marie-Francoise Avril,Thomas Jouary,Rüdiger Hein,Patrick Terheyden,Jun Aoi,Tatsuya Takenouchi,Oddbjorn Straume,César Martins,Guzel Mukhametshina,Paul C. Nathan +131 more
TL;DR: In this paper, the authors compared pembrolizumab versus placebo in patients with resected high-risk stage III melanoma, and showed that penglizumaab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median followup.
Journal ArticleDOI
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline
Jeanne Carter,Christina Lacchetti,Barbara L. Andersen,Debra L. Barton,Sage Bolte,Shari Damast,Michael A. Diefenbach,Katherine DuHamel,Judith Florendo,Patricia A. Ganz,Shari Goldfarb,Sigrun Hallmeyer,David M. Kushner,Julia H. Rowland +13 more
TL;DR: Both women and men experiencing vasomotor symptoms should be offered interventions for symptomatic improvement, including behavioral options such as cognitive behavioral therapy, slow breathing and hypnosis, and medications such as venlafaxine and gabapentin.
Journal ArticleDOI
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio,Karl D. Lewis,Lev V. Demidov,Mario Mandalà,Igor Bondarenko,Paolo A. Ascierto,Christopher Herbert,Andrzej Mackiewicz,Piotr Rutkowski,Alexander Guminski,Grant R. Goodman,B. Simmons,Chenglin Ye,Yibing Yan,Dirk Schadendorf,Gabriela Cinat,Luis Fein,Michael C. Brown,Andrew Haydon,Adnan Khattak,Catriona M. McNeil,Phillip Parente,Jeremy Power,Rachel Roberts-Thomson,Shahneen Sandhu,Craig Underhill,Suresh Varma,Thomas Berger,Ahmad Awada,Nathalie Blockx,Veronique Buyse,Jeroen Mebis,Fabio Franke,Sergio J Azevedo,Nicolas Silva Lazaretti,Rahima Jamal,Catalin Mihalcioiu,Teresa M. Petrella,Kerry J. Savage,Xinni Song,Ralph Wong,Nina Dabelic,Stjepko Plestina,Zeljko Vojnovic,Petr Arenberger,Ivo Kocak,Ivana Krajsová,Eugen Kubala,Bohuslav Melichar,Yvetta Vantuchova,Kadri Putnik,Brigitte Dréno,Caroline Dutriaux,Jean-Jacques Grob,Pascal Joly,Jean-Philippe Lacour,Nicolas Meyer,Laurent Mortier,Luc Thomas,Michael Fluck,Thilo Gambichler,Jessica C. Hassel,Axel Hauschild,Paul Donnellan,John McCaffrey,Derek G. Power,Samuel Ariad,Gil Bar-Sela,Daniel Hendler,Ilan G. Ron,Jacob Schachter,Paolo A. Ascierto,Alfredo Berruti,Luca Bianchi,Vanna Chiarion Sileni,Francesco Cognetti,Riccardo Danielli,Anna Maria Di Giacomo,Luca Gianni,Aron Goldhirsch,Michele Guida,Paolo Marchetti,Paola Queirolo,Armando Santoro,Ellen Kapiteijn,Paula Ferreira,Georgy Gafton,Yulia Makarova,Zoran Andric,Nada Babovic,Darjana Jovanovic,Lidija Sekulovic,Graham Lawrence Cohen,Lydia Dreosti,Daniel A. Vorobiof,Maria Teresa Curiel Garcia,Roberto Diaz Beveridge,Margarita Majem Tarruella,Ivan Marquez Rodas,Jose-M Puliats Rodriguez,Antonio Rueda Dominguez,Marianne Maroti,Karin Papworth,Olivier Michielin,Ewan Brown,Pippa Corrie,Mark Harries,Satish Kumar,Agustin Martin-Clavijo,Mark R. Middleton,Poulam M. Patel,Toby Talbot,Sanjiv S. Agarwala,Paul B. Chapman,Robert M. Conry,Gary Doolittle,Tara C. Gangadhar,Sigrun Hallmeyer,Omid Hamid,Leonel Hernandez-Aya,Douglas B. Johnson,Frederic Kass,Tatjana Kolevska,Scott Lunin,April K.S. Salama,Branimir I. Sikic,Bradley Somer,David R. Spigel,Eric D. Whitman +128 more
TL;DR: The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma and the result was not significant because of the prespecified hierarchical prerequisite for the primary disease-free survival analysis of cohort 2 to show a significant health benefit.
Journal ArticleDOI
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J Olson,Zeynep Eroglu,Bruce Brockstein,Andrew Poklepovic,Madhuri Bajaj,Sunil Babu,Sigrun Hallmeyer,Mario R. Velasco,Jose Lutzky,Emily F. Higgs,Riyue Bao,Timothy Carll,Brian W. Labadie,Thomas Krausz,Yuanyuan Zha,Theodore Karrison,Vernon K. Sondak,Thomas F. Gajewski,Nikhil I. Khushalani,Jason J. Luke +19 more
TL;DR: PURPOSECombination of antiprogrammed cell death protein-1 (PD-1) plus anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD -1 antibody alone as discussed by the authors.